Alector ALEC 深 沪
等待开盘 10-15 09:30:00 美东时间
1.88
+0.010
+0.53%
华盛通- 最 高1.9192
- 今 开1.84
- 成交量 291.24万股
- 最 低 1.82
- 昨 收 1.87
- 总市值 2.10亿
- 52周最高 2.76
- 市盈率 静 --
- 换手率 2.61%
- 52周最低 1.09
- 委 比 -95.11%
- 总股本 1.12亿
- 历史最高 43.32
- 量 比 0.81
- 振 幅 5.30%
- 历史最低 0.87
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股前瞻 | SK海力士势创“九连跌”！市值或失守万亿美元？苹果智能接入阿里千问大模型，10月底将测试！
势创“九连跌”！SK海力士盘前再跌近7%，或失守万亿美元市值？苹果智能接入阿里千问大模型！10月底将测试；CoreWeave引发AI信贷危机？盘前一度跌逾7%>>
46分钟前
美股大行评级 | 潜在涨幅325.53%！HC Wainwright维持Alector"买入"评级，目标价上调至8美元
今日重点评级关注：HC Wainwright & Co.：维持Alector"买入"评级，目标价从5美元升至8美元；摩根大通：维持ORIC Pharmaceuticals"超配"评级，目标价从23美元升至26美元
今天 12:36
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8
HC Wainwright & Co. analyst Andrew S. Fein maintains Alector (NASDAQ:ALEC) with a Buy and raises the price target from $5 to $8.
10-14 23:45
Alector Reprices Employee Stock Options to Boost Retention
An announcement from Alector ( ($ALEC) ) is now available. On October 13, 2026,...
10-14 21:28
美股大行评级 | 花旗看高AMD至800美元！富国上调Meta目标价至1000美元
今日重点评级关注：Jones Trading：维持Opus Genetics"买入"评级，目标价从10美元升至17美元；Citizens：维持Rezolute"跑赢大市"评级，目标价从11美元升至15美元
10-07 17:30
Alector surges on licensing agreement with Genentech
Alector (ALEC) is up ~22% in Monday morning trading after announcing a licensing deal for its AL050 program to treat Parkinson's and other neurodegenerative diseases with Roche (RHHBY)-owned Genentech...
10-05 22:11
Why is Alector Stock (ALEC) 60% Higher Today?
Shares in U.S. biotech firm Alector ($ALEC) surged 60% in pre-market trading to...
10-05 21:18
Alector Teams Up With Genentech On Potential Parkinson’s Treatment
Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide r...
10-05 19:02
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Alector has entered into an exclusive global licensing agreement with Genentech, granting them worldwide rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) designed to address GCase deficiency in Parkinson’s Disease. Alector will receive a $100 million upfront payment, up to $1.17 billion in milestone payments, and tiered royalties on net sales. Genentech will handle development, regulatory, manuf...
10-05 11:00
Alpha Buying: Follow the Money From NVIDIA and Merck
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of companies that already dominate their industries. NVIDIA understands what it takes ...
09-25 01:53
